top of page

Search Results

Results found for "Keltic Pharma Therapeutics"

  • Profiling Immune Cell and Platelet Transcriptomes

    signaling, influencing a wide array of physiological processes and serving as critical targets for therapeutic significant findings that enhance our understanding of GPCRs' roles in immune function and potential therapeutic macrophages suggest that these GPCRs could be targeted to modulate inflammatory responses, offering potential therapeutic the field continues to evolve, the insights gained from this research will be instrumental in shaping therapeutic

  • Understanding Orthosteric Binding: The Key to Drug Action

    This foundational knowledge guides researchers in the development of new therapeutics. It can inform decisions in drug design, improving therapeutic outcomes and reducing unwanted side effects This understanding can enhance your appreciation for drug development and therapeutic action.

  • Targeting GPCRs in the CNS: Advances in Drug Discovery Strategies

    and the complexity of the central nervous system (CNS) pose a challenge for developing successful therapeutics Emerging GPCR Therapeutic Targets in CNS Drug Discovery GPCRs have been studied for decades, but there Of the traditional GPCRs, CBRs are gaining ground as potential therapeutic targets in several CNS diseases One of the best tools to study therapeutic targets are fluorescent ligands , which are very useful in G-Protein-Coupled Receptors in CNS: A Potential Therapeutic Target for Intervention in Neurodegenerative

  • From Switches to Microcircuits: GPCR Biased Signaling and the Future of Drug Discovery

    Ligands designed to activate therapeutically beneficial pathways, while avoiding those associated with The therapeutic logic is sound: if signaling pathways are separable, they are potentially selectable. Family C), adhesion GPCRs, and Frizzled receptors (Family VI) have all attracted growing interest as new therapeutic both been implicated in COVID-19 pathophysiology — and represent active targets for receptor-directed therapeutic provides the needed mechanistic depth to define the functional selectivity  that may ultimately determine therapeutic

  • Inside Out: Mapping GPCRs from Membrane Codes to Market Moves

    Selection  – Master GPCR behavior beyond second messengers   Build sharper strategies for GPCR-targeted therapeutics receptor biology—and how they’re being used to de-orphanize GPCRs, explore autoantibodies, and uncover new therapeutic

  • New Podcast, Sweet Structures & $2.2B GPCR Moves

    mGluR2, and a big headline, Novo Nordisk’s $2.2B deal with Septerna to develop GPCR-targeted obesity therapeutics Biased signalling of Class B G protein-coupled receptor-targeted therapeutics .  

  • 📰 GPCR Weekly News, September 4 to 10, 2023

    Our partner, Domain Therapeutics, will attend the SACHS 23rd annual biotech event in Europe. Dr. Christopher Langmead and colleagues' work on the 5-HT2C receptor as a therapeutic target for substance GPCR Symposium on ''GPCRs as Therapeutic Modalities' Share your project with a 1-minute abstract video Protein and Exendin-P5 Biased Agonist Molecular and structural insights into the 5-HT2C receptor as a therapeutic teams up with addiction treatment maker Indivior to make digital therapeutics for substance use disorders

  • GPCR Internalization: When the Signal Moves Inside the Cell

    the cell depends on the ligand–receptor complex — and that distinction has direct implications for therapeutic Recycling Versus Degradation: The CCR5 Example The therapeutic stakes of this distinction are illustrated logic, the mechanistic distinctions, and the interpretive frameworks that connect trafficking data to therapeutic

  • Dr. GPCR and Celtarys Research Join Forces to Expand Access to Innovative GPCR Tools

    Celtarys’ cutting-edge fluorescent ligand technology and accelerate the development of GPCR-targeted therapeutics accelerate the adoption of our chemical tools and foster collaborations that turn receptor biology into therapeutic

  • Chemical Drug Matter : Rethinking the Molecules We Choose to Develop In Drug Discovery

    This approach reveals: Hidden target overlap New therapeutic hypotheses “Off-target” effects that may This reroutes discovery toward: Functionally selective ligands Better therapeutic windows More predictable What matters now is not the category , but the fit: Does the chemical matter support the therapeutic

  • 📰 GPCR Weekly News, December 11 to 17, 2023

    This week's highlights: Kudos to our partner, GPCR Therapeutics, for partnering with Bridge Biotherapeutics acids conjugation with [Cp*Rh(H2O)3]2+ by using the meta-dynamics/FMO3 approach Industry News GPCR Therapeutics - Providing the next generation of high-impact medicines Structure Therapeutics Provides Comprehensive Study Neurocrine opening two Phase 1 trials in oral Parkinson’s therapies Bearing Fruit: Deep Apple Therapeutics Launches to Screen AI-Generated Virtual Libraries AbbVie to Acquire Cerevel Therapeutics in Transformative

  • How a Failed Experiment Created a Powerful GPCR Imaging Tool

    not just the pancreas This tool helped clarify: Which neurons respond Which cell populations drive therapeutic metabolic therapy Guide how next-generation incretin drugs are designed Support cell-targeted conjugate therapeutic

  • Sweet taste receptor agonists attenuate macrophage IL‐1β expression and eosinophilic inflammation...

    Eosinophilic inflammation is a hallmark of refractory chronic rhinosinusitis (CRS) and considered a major therapeutic (ECRS) via macrophage IL‐1β overproduction, thereby suggesting autophagy regulation as a potential therapeutic We sought to investigate the therapeutic potential of autophagy‐enhancing agent, trehalose, or related Methods We investigated the therapeutic effects of trehalose and saccharin on macrophage IL‐1β production

  • 📰 GPCR Weekly News, February 5 to 11, 2024

    Fourth Quarter and Fiscal 2023 Financial Results and Provides Financial Expectations for 2024 Domain Therapeutics February 20, 2024 | Career Opportunities in Pharmacology and Drug Discovery March 13 - 15 | 9th German Pharm-Tox

  • 📰 GPCR Weekly News, June 12 to 18, 2023

    GPCRs in Neuroscience Orphan receptor GPR88 as a potential therapeutic target for CNS disorders - an Industry News Coherus to Acquire Surface Oncology Confo Therapeutics and AbCellera partner on GPCR-targeting Patent in Japan Proteros Biostructures GmbH Revolutionizes Metabolic Disorder Treatments Structure Therapeutics (June 28 - 30, 2023) NEW FREE Seminar Antibodies targeting Membrane Proteins - From Antigen to New Therapeutics

  • From Ox Liver to AI: How the History of Pharmacology Shapes Its Future

    👉 Join Terry’s Corner, your essential launchpad into the world of therapeutic science Unlock "The History

  • Illuminating C5aR Biology: The Role of Fluorescent Ligands in GPCR Research

    GPCRs are one of the most important families of therapeutic targets in the pharmaceutical industry molecular binding mechanism behind C5a and C5aR interaction is crucial for developing novel immunological therapeutics fluorescent probes have proven to be optimal tools to perform fluorescence-based assays to unlock the therapeutic Function, Structure and Therapeutic Potential of Complement C5a Receptors.

  • Adenosine receptor signalling in Alzheimer's disease

    Emerging evidence suggests adenosine G protein-coupled receptors (GPCRs) are promising therapeutic targets In this review, we provide an accessible summary of the literature on Alzheimer's disease and the therapeutic allosterism and the targeting of oligomers, which may increase drug discovery success and enhance the therapeutic

  • Adenosine receptor signalling in Alzheimer's disease

    Emerging evidence suggests adenosine G protein-coupled receptors (GPCRs) are promising therapeutic targets In this review, we provide an accessible summary of the literature on Alzheimer's disease and the therapeutic allosterism and the targeting of oligomers, which may increase drug discovery success and enhance the therapeutic

  • 📰 GPCR Weekly News, May 8 to 14, 2023

    2 Epilepsy Clinical Study’s Independent Interim Review Committee Recommends Continuing Study Addex Therapeutics Research Council (ERC) Addex Reports Q1 2023 Financial Results And Provides Corporate Update Structure Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights OMass Therapeutics presented at the BioEquity Conference British Patient Capital Invests £10m in next-generation drug development company OMass Therapeutics GPCR Events, Meetings, and Webinars ASPET 2023 - American Society for Pharmacology and Experimental Therapeutics

  • 📰 GPCR Weekly News, July 1 to 7, 2024

    September 5th to 26th, 2024 Overview: GPCRs have been and arguably still are the most prolific and fertile therapeutic trade-offs in whitefly G protein-coupled receptor kinases in hypertension: physiology, pathogenesis, and therapeutic proteins block the internalization of cognate GPCRs and disrupt downstream intracellular signaling Therapeutic acute and chronic relaxin-3 receptor (RXFP3) activation in the rat retrosplenial cortex Unveiling the therapeutic

  • 📰 GPCR Weekly News, October 2 to 8, 2023

    This week's highlight: Congrats to our partner GPCR Therapeutics, on their expansion into fibrosis with selectivity Industry News Sosei Heptares and Verily Nominate First G-protein-coupled receptor Target for Therapeutic Nearly $900K in NIH Funding to Discover Antibodies Against Difficult and Conserved Protein Targets GPCR Therapeutics

  • Target Residence Time: The Hidden Driver of In Vivo Efficacy

    Modeling tools to understand how restricted diffusion  in tissues like tumors slows offset and improves therapeutic drug hiding in fat tissue may stay in the body for days, but if it never reaches the target site, the therapeutic

  • How Fast Does a Drug Work?

    essential for pipeline efficiency: How fast a ligand binds (k₁) and how long it stays bound (k₂)  can alter therapeutic When does onset rate dictate therapeutic onset, and when does offset rate predict duration?

  • 📰 GPCR Weekly News, June 3 to June 9, 2024

    Adhesion GPCRs A correlation study of adhesion G protein-coupled receptors as potential therapeutic targets Services and Cube Biotech Collaborate to Enhance Cryo-EM Enabled Gene to Structure Workflow Domain Therapeutics ACTH-Dependent Cushing’s Syndrome (ADCS) Septerna Presents Preclinical Data at ENDO 2024 Highlighting Therapeutic

  • Propranolol: A “Pick and Roll” Team Player in Benign Tumors and Cancer Therapies

    Few therapeutic agents have shown benefits when administered alone, but a few more have demonstrated clear improvement when administered in combination with other therapeutic molecules. In 2008 (and for the first time in the clinic), the therapeutic benefits of the β-adrenergic receptor

  • 📰 GPCR Weekly News, September 11 to 17, 2023

    Kevin Wright on his new position as Director of Targeted and Immuno-oncology at GPCR Therapeutics, our GPCR Symposium on 'GPCRs as Therapeutic Modalities' with Richa Tyagi, Dr. Terry Kenakin, Dr. Kevin Wright Joins GPCR Therapeutics as Director of Targeted and Immuno-oncology Sosei Heptares Adds Lefkowitz's Career at Duke October 3, 2023, | FREE Seminar: Changing paradigm on Therapeutics targeting

  • 📰 GPCR Weekly News, August 28 to September 3, 2023

    GPCR Symposium on 'GPCRs as Therapeutic Modalities' Showcase your project with a 1-minute abstract video Bolsters Leadership Team as the Company Advances its Multi-Product Pipeline Toward Clinical Studies Confo Therapeutics 21st Annual Global Healthcare Conference CEO Raymond Stevens to Speak at STAT Future Summit on Obesity Therapeutics Function and Biased Signaling" at the DOT NEW October 3, 2023 | FREE Seminar: Changing paradigm on Therapeutics

  • 📰 GPCR Weekly News, May 1 to 7, 2023

    Industry News Addex Therapeutics to Release Q1 2023 Financial Results and Host Conference Call on May 11, 2023 Neurocrine Biosciences Reports First Quarter 2023 Financial Results Find Therapeutics welcomes critical, we cannot think about one size fits all” Dr Pina Cardarelli, Chief Scientific Officer, GPCR Therapeutics GPCR Events, Meetings, and Webinars ASPET 2023 - American Society for Pharmacology and Experimental Therapeutics

  • ⛵Sailing the GPCR Seas: Your Weekly Research Voyage! ⌿ Nov 11 - 17, 2024

    to GPCR Drug Discovery March 12 - 14, 2025 | NextGen Biomed 2025 March 25 - 28, 2025 | 10th German Pharm-Tox 20th World Congress of Basic and Clinical Pharmacology GPCR Jobs Scientist I Cell Biology - Tectonic Therapeutic

bottom of page